Lumos Pharma — Q2 2023 Earnings Presentation
10 slides from Lumos Pharma's earnings presentation, Aug 9, 2023
Slide 1: Second Quarter 2023 Financial Results & Clinical Update
1 Second Quarter 2023 Financial Results & Clinical Update August 9, 2023
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. (“Lumos,” “we,” “us” and “our”), and such content should be considered “Confidential Information” and covered by your confidentiality obligations to Lumos. This presentation is made
Slide 3: Agenda
3 Agenda • Lisa Miller, Senior Director of Investor Relations • Rick Hawkins, Chief Executive Officer & Chairman • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • Lori Lawley, Chief Financial Officer • Duke Pitukcheewanont, MD, SVP, Clinical
Slide 4: Primary Outcome Data for Two Phase 2 Trials in PGHD Expected Q4 2023
4 Primary Outcome Data for Two Phase 2 Trials in PGHD Expected Q4 2023 • Primary 6-month AHV & safety data on • ~20 subjects on 0.8 mg/kg/day LUM-201 • ~20 subjects on 1.6 mg/kg/day LUM-201 • ~20 subjects on 3.2 mg/kg/day LUM-201 • ~20 subjects on daily rhGH • 12-month AHV data on ~12 per cohort • 1
Slide 5: Expected Registrational Phase 3 Trial Design Based on Recent Pivotal Trials in PGHD
5 • n = ~180-200 • Randomized 2:1 LUM-201 to rhGH control arm • PEM(+) PGHD subjects • Peak stim GH ≥ 5 ng/ml after 1 LUM-201 dose • Baseline IGF-1 >30 ng/ml • rhGH treatment naïve • Multiple trial sites US & International • 12 months on therapy Expected Registrational Phase 3 Trial Design Based on
Slide 6: Novel LUM-201 Formulation for Phase 3 and Commercial Use
6 Novel LUM-201 Formulation for Phase 3 and Commercial Use Novel LUM-201 formulation • Mini-tablets inside of a capsule • Unique LUM-201 manufacturing techniques enabled novel formulation Advantages of novel formulation • Minimizes dose variability across wide weight range of patients on drug • Easy
Slide 7: Endocrine Society Meeting (ENDO) Oral Presentations on LUM-201
7 Endocrine Society Meeting (ENDO) Oral Presentations on LUM-201 Additional OraGrowtH212 Interim Data: • LUM-201 produced an increase in IGF-1 levels that remained within normal range and an increase in IGF-1 SDS > 0 • Consistent increase in AHV over baseline observed on LUM-201 with durable respons
Slide 8: Additional Highlights
8 Additional Highlights • Late-Breaking Abstract Accepted for Oral Presentation: Deconvolution Analysis: GH secretagogue (LUM-201) enhances growth in individuals with moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD) by enhancing endogenous GH secretion and increasing IGF-1, Cassorla,
Slide 9: Lumos Pharma Financial Information as of June 30, 2023
9 Lumos Pharma Financial Information as of June 30, 2023 Values in USD Cash, equivalents & short-term investments $50.9M Debt $0 Shares Outstanding 8.0M Cash Use per Quarter in 2023 $9.5-$10.5M Fiscal Year End December 31 LUMO Cash, cash equivalents, & short-term investments to support operations in
Slide 10: Overview
10 Overview Lead asset targeting children with growth disorders Novel Oral Rare Disease Asset Pipeline in a Product Solid Financial Position • Novel oral therapeutic asset, LUM-201, for growth hormone deficiency (GHD) disorders • LUM-201 acts within natural endocrine pathway, differentiated from inj